Eco Animal Health Group PLC (AIM:EAH) rose nearly 15% after hinting it would outdo market expectations this year after stronger than expected demand for its Aivlosin drug in Asia.
The AIM-listed research and developer of drugs for livestock said it had seen strong trading in the final quarter, pushed by higher demand in China and Asia, meaning revenue and pre-tax earnings would likely exceed expectations for the year to March 31.
"Our business has delivered good progress in key international markets especially Asia,” chief executive David Hallas said. “We look forward to providing a further update following the completion of the financial year.”
Aivlosin is an antibiotic used to treat a number of infectious diseases in pigs, chickens, pheasants and turkeys.
Shares climbed 14.8% to 112.5p.